Digi International Bolsters Digi Connect EZ Family of Device Servers with Launch of 8/16/32 Port Options
6.4.2023 15:00:00 EEST | Business Wire | Press release
Digi International, (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) connectivity products and services, today announced the launch of Digi Connect® EZ 8/16/32. This solution represents the latest in Digi’s line of next-generation device servers providing secure, scalable connectivity for business, commercial, and industrial automation applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005005/en/
Digi Connect EZ 8/16/32 comes with a one-year subscription to Digi’s LifeCycle Assurance Program, providing customers with access to Digi Remote Manager Premier edition and 24/7 expert technical support. (Photo: Business Wire)
The product expansion underscores Digi’s commitment to supporting critical industries spanning utilities, energy, aerospace, government, commercial, logistics and factory automation with intelligent end-to-end serial connectivity solutions. Combining state-of-the-art hardware with the robust Digi Accelerated Linux (DAL) operating system, the Digi Connect EZ 8/16/32 line offers a range of industry-leading features. These include cellular support and the unparalleled central management capabilities of Digi Remote Manager® (Digi RM). This platform enables in-depth, 360-degree visibility to configure, deploy, and manage remote assets securely.
Also included with Digi Connect EZ 8/16/32 is a one-year subscription to Digi’s LifeCycle Assurance Program, providing customers with access to Digi Remote Manager Premier edition and 24/7 expert technical support.
“We are excited to expand the Digi Connect EZ family, providing enhanced solutions and devices that enable our customers to conveniently and securely scale their operations today, while preemptively addressing the IIoT challenges of tomorrow,” said Brian Kirkendall, General Manager and Vice President of Infrastructure Management at Digi. “The incorporation and availability of our wider product features such as cellular support, central management with Digi RM, and round-the-clock expert assistance underscore Digi’s ongoing commitment to supporting customers throughout the entire product lifecycle.”
Hardware-enabled and software-defined, the Connect EZ family of products delivers a scalable solution that supports multiple serial interfaces in both industrial and non-industrial environments. Digi Connect EZ prevents data loss, providing state of the art communication technology to meet the needs of machine-to-machine serial communication customers all over the world. Additionally, the Connect EZ family offers an updated hardware platform that ensures longevity, manageability, and deployment flexibility. To manage critical serially connected equipment at scale, the Connect EZ family adheres to the following key attributes:
- Scalability — Simple click-to-connect deployment using Digi Navigator, with quick configuration providing easy integration for a wide range of use cases. Digi Connect EZ is truly easy to deploy and manage at scale throughout the product lifecycle with robust security, management and device health capabilities.
- Reliability — Built on top of the Digi TrustFence® design architecture and DAL operating system, Digi Connect EZ is designed for deployment in industrial environments to offer a secure, stable, and resilient platform for mission-critical connectivity, including LTE and Wi-Fi.
- Capability — Supports a wide range of industry standard and device-specific protocols using serial tunneling, and TCP/UDP connections or Digi’s patented RealPort® COM port redirector for remote native COM port access. Additionally, the built-in Python environment enables application development and customization at the device level, including event-based programmability, data conversion and full control of device connections.
“No matter the industry, no matter the challenge — from industrial automation to large scale manufacturing to secure communication of critical data — we’ve got our customers covered,” Kirkendall continued. “With the Connect EZ 8/16/32 expansion, we’re delivering the scalable and secure end-to-end connectivity solution our customers not only need, but that they deserve.”
Availability
Digi Connect EZ® 8/16/32 devices are available for immediate purchase now.
Explore the solutions here:
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services and solutions. We help our customers create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, we’ve helped our customers connect over 100 million things and growing. For more information, visit Digi's website at www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230406005005/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom